Megan Comerford
Overview
Explore the profile of Megan Comerford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fogel R, Comerford M, Chilukuri P, Orman E, Chalasani N, Lammert C
Interact J Med Res
. 2018 Dec;
7(2):e18.
PMID: 30567687
Background: Concurrent autoimmune illnesses contribute to increased medical burden and reduced quality of life in patients with autoimmune hepatitis (AIH). The frequency of coexisting autoimmune conditions among North American patients...
2.
Comerford M, Fogel R, Bailey J, Chilukuri P, Chalasani N, Lammert C
J Med Internet Res
. 2018 Jan;
20(1):e14.
PMID: 29348111
Background: Conventional approaches to participant recruitment are often inadequate in rare disease investigation. Social networking sites such as Facebook may provide a vehicle to circumvent common research limitations and pitfalls....
3.
Yates K, Deppe R, Comerford M, Masuoka H, Cummings O, Tonascia J, et al.
PLoS One
. 2017 Nov;
12(11):e0185813.
PMID: 29095942
Aim: Serum high mobility group box 1 protein (HMGB1) is a proinflammatory molecule that could potentially serve as a biomarker for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)...
4.
Puri P, Liangpunsakul S, Christensen J, Shah V, Kamath P, Gores G, et al.
Hepatology
. 2017 Oct;
67(4):1284-1302.
PMID: 29083504
Conclusion: Heavy alcohol consumption appears to be the primary driver of changes in the circulating microbiome associated with a shift in its inferred metabolic functions. (Hepatology 2018;67:1284-1302).
5.
Comerford M, Lourens S, Liangpunsakul S, Chalasani N, Sanyal A, Shah V, et al.
Alcohol Clin Exp Res
. 2017 Oct;
41(12):2000-2006.
PMID: 28981151
The TREAT Consortium has carried out clinical studies on alcoholic hepatitis (AH) for over 4 years. We encountered problems with participant recruitment, retention, and eligibility for specific protocols. To improve...
6.
Corey K, Gawrieh S, deLemos A, Zheng H, Scanga A, Haglund J, et al.
World J Hepatol
. 2017 Mar;
9(7):385-390.
PMID: 28321274
Aim: To identify risk factors associated with hepatocellular carcinoma (HCC), describe tumor characteristics and treatments pursed for a cohort of individuals with nonalcoholic steatohepatitis (NASH) cirrhosis. Methods: We conducted a...
7.
Carr R, Dhir R, Mahadev K, Comerford M, Chalasani N, Ahima R
Clin Gastroenterol Hepatol
. 2016 Aug;
15(1):145-147.
PMID: 27567691
No abstract available.
8.
Lammert C, Comerford M, Love J, Bailey J
Gastroenterology
. 2015 Aug;
149(4):839-43.
PMID: 26306768
No abstract available.
9.
Masuoka H, Vuppalanchi R, Deppe R, Bybee P, Comerford M, Liangpunsakul S, et al.
Dig Dis Sci
. 2015 Jul;
60(12):3642-6.
PMID: 26195313
Background And Aim: Hepatocyte apoptosis or necrosis from accumulation of bile salts may play an important role in the disease progression of primary sclerosing cholangitis (PSC). The aim of the...
10.
Bell L, Wulff J, Comerford M, Vuppalanchi R, Chalasani N
Liver Int
. 2014 Sep;
35(1):263-74.
PMID: 25181933
Background & Aims: A greater understanding of cholestatic disease is necessary to advance diagnostic tools and therapeutic options for conditions such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis...